BioSpace News Archive

First-time positive results of EO2 Oxygen Delivery System with frequent debridement

The mycosis fungoides therapeutics market report has been added to Technavio’s catalog.

Northwell Health hospitals are now using a patented form of ultraviolet technology to reduce pathogens in the environment that present the risk of hospital-acquired infections.

George Clinical, a global scientifically-backed clinical research organization, has expanded its presence in Europe with the opening of a larger and more sophisticated location in the United Kingdom.

Diabetes occurs 3 times more often among normal-weight Hawaiians and Pacific Islanders than among normal-weight whites, Kaiser Permanente research finds [19-September-2019] OAKLAND, Calif. , Sept. 19, 2019 /PRNewswire/ -- Being overweight or obese is commonly associated with diabetes, but a new Kaiser Permanente study finds the connection differs widely by race or eth

One former employee and a participant in the Company’s previous share option program, not being a primary insider, has exercised a total number of 5,775 options through exercise of a corresponding number of free-standing warrants.

TSO3 Inc. (“TSO3" or the “Company”) (TSX: TOS) confirms that the consideration payable to the shareholders of the Company (the “Shareholders”) pursuant to the plan of arrangement (the “Arrangement”) involving the Company, Stryker Corporation (“Stryker”) and 9402-4874 Québec Inc. (the “Purchaser”), a subsidiary of Stryker, continues to be CAD $0.43 per share.

Global professional services firm ZS has launched Clinical Design Center, an integrated technology platform and services solution that allows cross-functional teams within pharmaceutical organizations to collaborate in a virtual environment to make better data-driven decisions on clinical trial design and operations.

Elysium Health, Inc.,™ a life sciences company developing clinically validated health products based on aging research, today announced the acceptance of an Investigational New Drug (“IND”) application by the Food and Drug Administration (FDA) to evaluate the efficacy of BASIS™ for the prevention of acute kidney injury (AKI) in surgical cardiac patients.

The new drug application (NDA) of Chiglitazar (Bilessglu®), an innovative new chemical entity (Category 1 chemical drug) for type 2 diabetes discovered and developed by Shenzhen Chipscreen Biosciences (Stock Symbol: 688321.SH), has been accepted by center for drug evaluation of NMPA on September 19, 2019